Krabbe Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Krabbe Disease (KD) is an autosomal recessive neurodegenerative disorder caused by a lysosomal enzyme galactocerebrosidase deficiency. GALC, the gene that encodes galactocerebrosidase, is found on chromosome 14q31.3. Feeding difficulties, hyperirritability, episodic fever of unknown origin, psychomotor regression, and convulsive seizures are typical clinical features of "early infantile" or "early onset" Krabbe disease. Fundoscopic inspection can reveal macular cherry red spots. Later, patients with early onset Krabbe Disease (KD) reach the “burnout” stage with blindness, hypotonia, and decerebration without any voluntary movements. Both microcephaly and macrocephaly occur depending on the disease stage.
·
In 2020, the estimated Krabbe disease (KD)
prevalence ranged between 1.5 to 1.75 cases per 100,000 population.
·
10% of patients manifested at 7–12 months, 22%
between 13 months and ten years, and 5% were in their adolescent/adult age.
Thelansis’s “Krabbe Disease (KD)
Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Krabbe Disease (KD) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Krabbe Disease (KD) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Krabbe Disease (KD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment